Mass spectrometry based assessment chimeric mouse liver metabolite profiles following oral dosing of troglitazone

Importance of the Topic

Chimeric mice repopulated with human hepatocytes provide a powerful in vivo platform to model human drug metabolism and predict potential metabolites that may not be observed in standard animal models. This approach enhances the translational relevance of preclinical safety studies and supports regulatory assessment by identifying human-specific metabolic pathways early in drug development.

Objectives and Study Overview

This study aimed to compare the metabolic fate of the antidiabetic agent troglitazone in chimeric PhoenixBio (PXB) mice versus severe combined immunodeficiency (SCID) controls. Troglitazone was administered orally at 300 and 600 mg/kg for seven days. The goals were to characterize human-like phase I/II metabolites in PXB livers and to profile endogenous lipid changes associated with the humanized hepatic system.

Methodology and Instrumentation

Sample Preparation and Chromatography

• Aqueous and organic extracts of liver tissue were prepared from PXB and SCID mice.
• Chromatographic separation used a Phenomenex Kinetex C18 column (2.1 × 100 mm, 1.7 µm) with a water/acetonitrile gradient (0.1% formic acid, 10 mM ammonium acetate) at 0.6 mL/min and 30 °C.

Mass Spectrometry and Data Analysis

• High-resolution LCMS-IT-TOF (Shimadzu) collected positive/negative MS and MS² data (m/z 150–1250) with polarity switching.
• Metabolite profiling used Profiling Solution; targeted metabolite identification employed MetID Solution based on accurate mass, isotope scoring, and MSⁿ fragmentation.
• Endogenous lipid profiling applied principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) via Simca-P.

Main Results and Discussion

Troglitazone Metabolism

• PXB mice generated human-like sulfate conjugates of troglitazone at higher levels than SCID controls, consistent with human metabolic pathways.
• SCID mice showed relatively greater glucuronidation compared with PXB, reflecting murine phase II preferences.
• MSⁿ fragmentation confirmed structures of parent drug, sulfate, glucuronide, hydroxy-sulfate, and dihydroxy metabolites with mass errors <10 ppm.

Endogenous Lipid Profiling

• PCA separated PXB and SCID groups regardless of troglitazone dose, indicating intrinsic lipidomic differences.
• OPLS-DA S-plot identified key ions; two diacylglycerophosphocholine species were significantly elevated in PXB livers.
• Certain lipid changes correlated with troglitazone dosing, suggesting the drug’s secondary impact on hepatic lipid metabolism.

Benefits and Practical Applications of the Method

• Humanized chimeric mice enable early detection of human-specific drug metabolites, improving safety risk assessment.
• Combined use of accurate-mass MSⁿ and specialized software increases confidence in metabolite identification without authentic standards.
• Endogenous lipid profiling offers insights into host liver biology and drug-induced perturbations, aiding mechanistic toxicology.

Future Trends and Potential Applications

• Integration of chimeric mouse models with multi-omics approaches (proteomics, transcriptomics) to deepen mechanistic understanding of drug effects.
• Development of higher-throughput workflows and advanced data-mining tools for comprehensive biomarker discovery.
• Application in precision medicine to predict individual metabolic phenotypes and tailor dosing strategies.

Conclusion

PhoenixBio chimeric mice recapitulate human troglitazone metabolism, notably sulfate conjugation, while control SCID mice reflect murine glucuronidation bias. High-resolution MSⁿ and advanced software facilitated robust identification of drug and lipid metabolites. This platform supports improved preclinical metabolic assessment and reveals endogenous lipid differences inherent to humanized livers.

Reference

Castro-Perez, J., et al. (2010) Comprehensive lipid profiling using high-resolution mass spectrometry. Analytical Chemistry, 82(9), 3862–3868.